REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regeneron Pharmaceuticals Inc (REGN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has positive catalysts such as Dupixent's approval in Japan and a promising pipeline, the recent financial performance shows a decline in net income and EPS. Additionally, technical indicators suggest a neutral to slightly bearish trend, and there are no strong trading signals or recent significant insider or congress trading activity to support an immediate buy decision.
The MACD histogram is negative (-0.815) and contracting, indicating weak momentum. RSI is neutral at 58.442, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 748.39, with resistance at 764.949 and support at 731.83. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Dupixent's approval in Japan for moderate-to-severe bullous pemphigoid, marking its seventh indication in the country. Analysts highlight the potential of Regeneron's pipeline and Dupixent's indication expansion as underappreciated growth drivers.
Concerns about Eylea headwinds and uncertainty around Dupixent's loss of exclusivity (LOE). Technical indicators do not show strong bullish momentum.
In Q4 2025, revenue increased by 2.51% YoY to $3.88 billion, but net income dropped by 7.97% YoY to $844.6 million. EPS also declined by 2.97% YoY to $7.84. Gross margin improved slightly by 1.12% YoY to 89.4%.
Analysts have mixed views. Barclays initiated coverage with an Overweight rating and a $923 price target, citing undervalued pipeline opportunities. Guggenheim and JPMorgan are optimistic with price targets of $975 and $950, respectively, highlighting Dupixent's performance and upcoming catalysts. However, RBC and Wells Fargo maintain more cautious views with Equal Weight ratings, citing potential headwinds and lack of near-term catalysts.
